Delivery Order SPE2DB22D2206-SPE2DB25FGS55
Award Date 4/24/25
Potential Completion Date 5/15/25
Potential Value $120K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $48,077.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on September 19, 2025, with an ultimate completion date of October 10, 2025. This non-competitive delivery order was placed against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a $136,567.97 delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials on April 24, 2025, with completion expected by May 15, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $96,154.24 to AmerisourceBergen Drug Corp for the supply of Ocrevus (ocrelizumab) 300 mg/10 mL vials. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 24, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. Ocrevus is a monoclonal antibody therapeutic used to treat multiple sclerosis,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ocrevus 300 mg/10 mL vials valued at $32,694.46 under a firm fixed-price contract. The delivery order is non-set-aside and competitively awarded, with a completion date of June 24, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $72,115.74. The contract, which was competitively awarded with no set-aside designation, carries a firm fixed price structure and is scheduled for completion by August 21, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed price delivery order with an ultimate completion date of June 24, 2025, and represents a non-competitive, non-set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $12,019.28 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, scheduled for completion by September 22, 2025. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child contract issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,019.28 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This firm fixed price contract, awarded on July 23, 2025, with an ultimate completion date of August 13, 2025, represents a competitively awarded, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $72,115.74 to AmerisourceBergen Drug Corp for the supply of Ocrevus (300 mg/10 mL vial) pharmaceutical product. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 2, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 18, 2025. The contract is firm fixed price with no set-aside designation and is scheduled for completion by September 9, 2025. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery...